Upending Purdue Pharma’s settlement does little to help today’s opioid crisis, advocates say

The drug policy world has been left torn by the Supreme Court’s ruling on Thursday that Purdue Pharma’s bankruptcy deal could not move forward if it included legal protections for the company’s billionaire owners.

In one camp are those who were eager to see the agreed-upon $6 billion settlement put to work preventing and treating opioid addiction. In the other are those who found the prospect of shielding the Sackler family from civil lawsuits to be indefensible.

But there is a third camp, too: One that argues Purdue, its infamous pain drug OxyContin, and the overall scandal are of little relevance to today’s overdose epidemic, in which fentanyl, methamphetamine, and other illicit drugs combine to kill over 110,000 Americans each year.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In